We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-5.00 | -0.29% | 1,700.20 | 1,700.40 | 1,701.40 | 1,703.60 | 1,699.40 | 1,701.60 | 77,357 | 08:07:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.25 | 70.2B |
TIDMGSK
RNS Number : 3593X
GlaxoSmithKline PLC
20 February 2017
GlaxoSmithKline plc (the 'Company')
Shares withheld or sold to meet tax liabilities
Following the vesting of awards granted in 2014 under the GlaxoSmithKline 2009 Performance Share Plan on 16 February 2017 and as notified on 17 February 2017, the notifications that follow reflect changes in the interests of Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them ('PCA") in Ordinary Shares and in American Depositary Shares (ADSs) of the Company arising from the sale or withholding of Ordinary Shares or ADSs to meet tax liabilities. This notification also includes the sale further to the vesting of awards granted in 2012 to Sir Andrew Witty which were subject to an additional holding period.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA') === ======================================================================= a) Name Sir Andrew Witty === ======================== ============================================= b) Position/status Chief Executive Officer === ======================== ============================================= c) Initial notification/ Initial notification amendment === ======================== ============================================= 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ======================================================================= a) Name GlaxoSmithKline plc === ======================== ============================================= b) LEI 5493000HZTVUYLO1D793 === ======================== ============================================= 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ======================================================================= a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== ============================================= b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities for the vesting of awards granted in 2012 and 2014 under the Company's 2009 Performance Share Plan. === ======================== ============================================= c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP16.2437 9,057 ------------ ---------- GBP16.2437 166 ------------ ---------- GBP16.2437 55,441 ------------ ---------- === ======================== ============================================= d) Aggregated information 64,664 GBP16.2437 Aggregated volume Price === ======================== ============================================= e) Date of the transaction 2017-02-16 === ======================== ============================================= f) Place of the London Stock Exchange (XLON) transaction === ======================== ============================================= 1. Details of PDMR/person closely associated with them ('PCA') === ===================================================================== a) Name Ms E Walmsley === ======================== =========================================== b) Position/status CEO Designate === ======================== =========================================== c) Initial notification/ Initial notification amendment === ======================== =========================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ===================================================================== a) Name GlaxoSmithKline plc === ======================== =========================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =========================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ===================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== =========================================== b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =========================================== c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP16.2437 19,218 ------------ ---------- === ======================== =========================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =========================================== e) Date of the transaction 2017-02-16 === ======================== =========================================== f) Place of the London Stock Exchange (XLON) transaction === ======================== =========================================== 1. Details of PDMR/person closely associated with them ('PCA') === ===================================================================== a) Name Mr R G Connor === ======================== =========================================== b) Position/status President, Global Manufacturing and Supply === ======================== =========================================== c) Initial notification/ Initial notification amendment === ======================== =========================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ===================================================================== a) Name GlaxoSmithKline plc === ======================== =========================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =========================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ===================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== =========================================== b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =========================================== c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP16.2437 14,957 ------------ ---------- === ======================== =========================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =========================================== e) Date of the transaction 2017-02-16 === ======================== =========================================== f) Place of the London Stock Exchange (XLON) transaction === ======================== =========================================== 1. Details of PDMR/person closely associated with them ('PCA') === ===================================================================== a) Name Mr S Dingemans === ======================== =========================================== b) Position/status Chief Financial Officer === ======================== =========================================== c) Initial notification/ Initial notification amendment === ======================== =========================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ===================================================================== a) Name GlaxoSmithKline plc === ======================== =========================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =========================================== 3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ===================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== =========================================== b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =========================================== c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP16.2437 32,529 ------------ ---------- === ======================== =========================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =========================================== e) Date of the transaction 2017-02-16 === ======================== =========================================== f) Place of the London Stock Exchange (XLON) transaction === ======================== =========================================== 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================= a) Name Mr N Hirons === ======================== =============================================== b) Position/status SVP, Global Ethics & Compliance === ======================== =============================================== c) Initial notification/ Initial notification amendment === ======================== =============================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================= a) Name GlaxoSmithKline plc === ======================== =============================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =============================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================= a) Description of GlaxoSmithKline plc American Depositary the financial Shares ('ADSs') instrument ISIN: US37733W1053 === ======================== =============================================== b) Nature of the The withholding of ADSs to meet tax liabilities transaction further to the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =============================================== c) Price(s) and Price(s) Volume(s) volume(s) --------- ---------- $40.57 1,255 --------- ---------- === ======================== =============================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =============================================== e) Date of the transaction 2017-02-16 === ======================== =============================================== f) Place of the n/a transaction === ======================== =============================================== 1. Details of PDMR/person closely associated with them ('PCA') === ===================================================================== a) Name Mr S A Hussain === ======================== =========================================== b) Position/status President, Global Pharmaceuticals === ======================== =========================================== c) Initial notification/ Initial notification amendment === ======================== =========================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ===================================================================== a) Name GlaxoSmithKline plc === ======================== =========================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =========================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ===================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== =========================================== b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =========================================== c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP16.2437 27,371 ------------ ---------- === ======================== =========================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =========================================== e) Date of the transaction 2017-02-16 === ======================== =========================================== f) Place of the London Stock Exchange (XLON) transaction === ======================== =========================================== 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================= a) Name Mr B McNamara === ======================== =============================================== b) Position/status CEO, Consumer Healthcare === ======================== =============================================== c) Initial notification/ Initial notification amendment === ======================== =============================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================= a) Name GlaxoSmithKline plc === ======================== =============================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =============================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================= a) Description of GlaxoSmithKline plc American Depositary the financial Shares ('ADSs') instrument ISIN: US37733W1053 === ======================== =============================================== b) Nature of the The withholding of ADSs to meet tax liabilities transaction further to the vesting of awards granted in 2015 under the Company's 2009 Performance Share Plan. === ======================== =============================================== c) Price(s) and Price(s) Volume(s) volume(s) --------- ---------- $40.57 10,082 --------- ---------- === ======================== =============================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =============================================== e) Date of the transaction 2017-02-16 === ======================== =============================================== f) Place of the n/a transaction === ======================== =============================================== 1. Details of PDMR/person closely associated with them ('PCA') === ===================================================================== a) Name Mr D S Redfern === ======================== =========================================== b) Position/status Chief Strategy Officer === ======================== =========================================== c) Initial notification/ Initial notification amendment
=== ======================== =========================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ===================================================================== a) Name GlaxoSmithKline plc === ======================== =========================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =========================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ===================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== =========================================== b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =========================================== c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP16.2437 10,738 ------------ ---------- === ======================== =========================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =========================================== e) Date of the transaction 2017-02-16 === ======================== =========================================== f) Place of the London Stock Exchange (XLON) transaction === ======================== =========================================== 1. Details of PDMR/person closely associated with them ('PCA') === ===================================================================== a) Name Ms C Thomas === ======================== =========================================== b) Position/status SVP, Human Resources === ======================== =========================================== c) Initial notification/ Initial notification amendment === ======================== =========================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ===================================================================== a) Name GlaxoSmithKline plc === ======================== =========================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =========================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ===================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== =========================================== b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =========================================== c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP16.2437 15,320 ------------ ---------- === ======================== =========================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =========================================== e) Date of the transaction 2017-02-16 === ======================== =========================================== f) Place of the London Stock Exchange (XLON) transaction === ======================== =========================================== 1. Details of PDMR/person closely associated with them ('PCA') === ===================================================================== a) Name Mr P C Thomson === ======================== =========================================== b) Position/status SVP, Communications & Government Affairs === ======================== =========================================== c) Initial notification/ Initial notification amendment === ======================== =========================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ===================================================================== a) Name GlaxoSmithKline plc === ======================== =========================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =========================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ===================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== =========================================== b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =========================================== c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP16.2437 7,307 ------------ ---------- === ======================== =========================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =========================================== e) Date of the transaction 2017-02-16 === ======================== =========================================== f) Place of the London Stock Exchange (XLON) transaction === ======================== =========================================== 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================= a) Name Mr D E Troy === ======================== =============================================== b) Position/status SVP & General Counsel === ======================== =============================================== c) Initial notification/ Initial notification amendment === ======================== =============================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================= a) Name GlaxoSmithKline plc === ======================== =============================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =============================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================= a) Description of GlaxoSmithKline plc American Depositary the financial Shares ('ADSs') instrument ISIN: US37733W1053 === ======================== =============================================== b) Nature of the The withholding of ADSs to meet tax liabilities transaction further to the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =============================================== c) Price(s) and Price(s) Volume(s) volume(s) --------- ---------- $40.57 13,035 --------- ---------- === ======================== =============================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =============================================== e) Date of the transaction 2017-02-16 === ======================== =============================================== f) Place of the n/a transaction
=== ======================== =============================================== 1. Details of PDMR/person closely associated with them ('PCA') === ===================================================================== a) Name Dr P J T Vallance === ======================== =========================================== b) Position/status President, R&D === ======================== =========================================== c) Initial notification/ Initial notification amendment === ======================== =========================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ===================================================================== a) Name GlaxoSmithKline plc === ======================== =========================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =========================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ===================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== =========================================== b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =========================================== c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP16.2437 32,996 ------------ ---------- === ======================== =========================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =========================================== e) Date of the transaction 2017-02-16 === ======================== =========================================== f) Place of the London Stock Exchange (XLON) transaction === ======================== =========================================== 1. Details of PDMR/person closely associated with them ('PCA') === ===================================================================== a) Name Mrs V A Whyte === ======================== =========================================== b) Position/status Company Secretary === ======================== =========================================== c) Initial notification/ Initial notification amendment === ======================== =========================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ===================================================================== a) Name GlaxoSmithKline plc === ======================== =========================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =========================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ===================================================================== a) Description of Ordinary shares of 25 pence each ('Ordinary the financial Shares') instrument ISIN: GB0009252882 === ======================== =========================================== b) Nature of the The sale of Ordinary Shares to meet tax transaction liabilities for the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =========================================== c) Price(s) and Price(s) Volume(s) volume(s) ------------ ---------- GBP16.2437 2,197 ------------ ---------- === ======================== =========================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =========================================== e) Date of the transaction 2017-02-16 === ======================== =========================================== f) Place of the London Stock Exchange (XLON) transaction === ======================== =========================================== 1. Details of PDMR/person closely associated with them ('PCA') === ========================================================================= a) Name Dr K Slaoui === ======================== =============================================== b) Position/status PCA of Dr M M Slaoui (Chairman, Global Vaccines) === ======================== =============================================== c) Initial notification/ Initial notification amendment === ======================== =============================================== 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor === ========================================================================= a) Name GlaxoSmithKline plc === ======================== =============================================== b) LEI 5493000HZTVUYLO1D793 === ======================== =============================================== 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted === ========================================================================= a) Description of GlaxoSmithKline plc American Depositary the financial Shares ('ADSs') instrument ISIN: US37733W1053 === ======================== =============================================== b) Nature of the The withholding of ADSs to meet tax liabilities transaction further to the vesting of awards granted in 2014 under the Company's 2009 Performance Share Plan. === ======================== =============================================== c) Price(s) and Price(s) Volume(s) volume(s) --------- ---------- $40.57 249 --------- ---------- === ======================== =============================================== d) Aggregated information n/a (single transaction) Aggregated volume Price === ======================== =============================================== e) Date of the transaction 2017-02-16 === ======================== =============================================== f) Place of the n/a transaction === ======================== ===============================================
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEBLFLDLFEBBE
(END) Dow Jones Newswires
February 20, 2017 10:55 ET (15:55 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions